MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · The Journal of invasive cardiology · 2018

Favorable Short-Term and Long-Term Outcomes Among Patients With Prior History of Malignancy Undergoing Transcatheter Aortic Valve Implantation.

Berkovitch Anat, Guetta Victor, Barbash Israel M, Fink Noam, Regev Ehud, Maor Elad, Vered Yotam, Grossman Yoni, Younis Arwa, Kuperstein Rafael, Feinberg Micha, Asher Elad, Segev Amit, Fefer Paul

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Transcatheter aortic valve replacement (TAVR) is now the treatment of choice for high-surgical risk patients with symptomatic aortic stenosis. Little is known regarding the outcome of TAVR in patients with previous malignancy.

METHODS

We investigated 477 patients who underwent TAVR in a tertiary medical center. Subjects were divided into two groups according to malignancy status: no history of malignancy (n = 386) and positive history of malignancy (n = 91).

RESULTS

Mean age of the study population was 81 ± 7 years, and 52% were men. No major differences in baseline characteristics were found between groups. All-cause mortality was 24% for both malignancy and non-malignancy groups at a mean follow-up of 851 ± 629 days. Kaplan-Meier survival analysis demonstrated no difference in all-cause mortality between groups. Multivariate Cox regression analysis showed that malignancy status did not affect prognosis regarding overall mortality (hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.5-1.4; P=.46). However, cancer therapy administered within 12-months of TAVR was significantly associated with increased total mortality among patients undergoing TAVR (HR, 4.38; 95% CI, 1.14-16.77; P=.03).

CONCLUSIONS

Malignancy is a common comorbidity among TAVR candidates. Mere history of malignancy among elderly patients does not adversely affect short-term or long-term outcomes after TAVR; however, history of recent (<1 year) cancer-related treatment increases the risk for long-term mortality after TAVR. Decisions regarding TAVR among oncological patients should be individualized according to their malignancy status and anticipated life expectancy.

Для цитирования: Berkovitch Anat, Guetta Victor, Barbash Israel M, Fink Noam, Regev Ehud, Maor Elad, Vered Yotam, Grossman Yoni, Younis Arwa, Kuperstein Rafael, Feinberg Micha, Asher Elad, Segev Amit, Fefer Paul. Favorable Short-Term and Long-Term Outcomes Among Patients With Prior History of Malignancy Undergoing Transcatheter Aortic Valve Implantation.. The Journal of invasive cardiology. 2018.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.